Siemens Medical Systems has named John Pavlidis, formerly vice president of the company’s U.S. MRI division, to the post of president of the company’s ultrasound division in Issaquah, WA. Pavlidis joined Siemens in 1990 as MRI product
Siemens Medical Systems has named John Pavlidis, formerly vice president of the companys U.S. MRI division, to the post of president of the companys ultrasound division in Issaquah, WA. Pavlidis joined Siemens in 1990 as MRI product specialist, and has served in its MRI unit in both Iselin, NJ, and Erlangen, Germany. He replaces Wolfgang Reim, who has left the company. The firm also named two other ultrasound executives to new posts: David Quist is now vice president of marketing and sales support, and John Benson is vice president of product creation.
Siemens has also appointed Joe Camaratta to the post of vice president for marketing, sales, and service. He replaces Alex Stein, who has left the position for another within Siemens. Camarattas duties will include strategic planning, program development, and marketing communications for Siemens Iselin-based divisions. He joined Siemens in 1984, and has previously served as vice president for international marketing in Siemens Medical Engineering Groups MRI division in Erlangen, and as manager for the companys MRI division.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.